Izci, Hava
Punie, Kevin
Waumans, Lise
Laenen, Annouschka
Wildiers, Hans
Verdoodt, Freija
Desmedt, Christine
Ardui, Jan
Smeets, Ann
Han, Sileny N.
Nevelsteen, Ines
Neven, Patrick
Floris, Giuseppe
Article History
Received: 28 June 2022
Accepted: 26 December 2022
First Online: 28 December 2022
Competing interests
: The Authors declare no Competing Non-Financial Interests but the following Competing Financial Interests: K.P.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Mundi Pharma, Novartis, Pfizer, Pierre Fabre, Hoffmann/La Roche, Sanofi, Teva, Vifor Pharma. K.P. received travel support from AstraZeneca, Novartis, Pfizer, PharmaMar, Hoffmann/La Roche. K.P. received speaker fees and honoraria for advisory/consultancy roles from AstraZeneca, Gilead Sciences, Novartis, Roche and Seattle Genetics (all outside the submitted work). H.W.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from AstraZeneca, Daiichi Sankyo/Lily, Lilly, PSI, KCE, Immutep Pty, MSD, AstraZeneca Pharmaceuticals Ireland, CRO, Daiichi Sankyo, Lilly, Roche, and Daiichi Sankyo. Travel support from Pfizer and Roche, and honoraria from Eisai, AstraZeneca and MSD. P.N.’s institution received speaker fees, honoraria for advisory/consultancy roles and/or research funding from Lilly, Novartis, Pfizer, Radius Health and Roche. Travel support from Lilly, Pfizer and Roche.